PROSION Therapeutics
A role at PROSION Therapeutics focusing on contributing to innovative cancer treatment technology in a dynamic and international biotech environment.
Headquarters
Cologne, North Rhine-Westphalia, Germany
Company Size
1-10 employees
Founded
2020
PROSION Therapeutics is a drug development company focused on "redefining druggability" by applying cutting‑edge technologies to unlock targets previously considered undruggable. Using platform-based discovery approaches, they generate and advance novel therapeutic candidates to address highly unmet medical needs. PROSION aims to translate challenging target biology into medicines that expand treatment options for patients where existing modalities fall short.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for PROSION Therapeutics.